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Abstract Acute coronary syndromes are frequently caused by
“vulnerable” coronary plaques with a lipid-rich core. In 1993
near-infrared spectroscopy (NIRS) was first used to detect the
lipid (cholesterol) content of atherosclerotic plaques in an ex-
perimental animal study. NIRS was then carefully validated
using human atherosclerotic plaques (ex vivo), and has subse-
quently been developed for intracoronary imaging in humans,
for which now an FDA-approved catheter-based NIRS system
is available. NIRS provides a “chemogram” of the coronary
artery wall and is used to detect lipid-rich plaques. Using this
technology, recent studies have shown that lipid-rich plaques
are very frequent in the culprit lesion of patients with an acute
coronary syndrome, and are also common in non-culprit coro-
nary lesions in these patients as compared to patients with
stable coronary disease. First studies are evaluating the impact
of statin therapy on coronary NIRS-detected lipid cores.
Intracoronary NIRS imaging represents a highly interesting
method for coronary plaque characterization in humans and
may become a valuable tool for the development of novel
therapies aiming to impact on the biology of human coronary
artery plaques, likely in combination with other intracoronary
imaging techniques, such as optical coherence tomography.
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Introduction
Atherosclerotic plaques with a large lipid core are a frequent
cause of acute coronary syndromes [1]. In 1993 near-infrared
spectroscopy (NIRS) was first used for atherosclerotic plaque
imaging in an experimental animal model [2]. In further
ex vivo validation studies, NIRS was found to accurately
detect the lipid (cholesterol) content of human atherosclerotic
plaques [3]. In 2001, a device prototype for intracoronary
imaging was developed [4]. Recently, NIRS received US
Food and Drug Administration approval [5]. NIRS provides
a “chemogram” of the wall of the coronary artery and aims to
detect lipid-rich plaques [6].
NIRS Catheter
A commercially available catheter-basedNIRS imaging system
has been developed. This NIRS imaging system consists of a
3.2 French catheter (InfraReDx, Burlington, Massachusetts,
USA), a pullback, rotation device, and a dedicated console
comprising a laser light source and a computer for algorithmic
data processing [7]. The catheter comprises the rotating core
with optical fibers that deliver and collect near-infrared light
[7]. The light is emitted into a sample by the NIR spectrometer,
which subsequently measures the proportion of light that is
returned over the range of optical wavelength [6]. The NIRS
system uses wave lengths of 800 to 2500 nm, converting a
diffuse reflectance signal from an object to produce a spectrum.
Subsequently, a computer analyzes the spectra and produces an
algorithm to demonstrate a chemogram, that corresponds
strongly to the lipid content [5] (Figs. 1 and 2).
Experience Using NIRS for Coronary Plaque Imaging
in Humans in Vivo
Non-invasive imaging modalities including computed tomog-
raphy or magnetic resonance have a limited resolution for
precise plaque characterization [5]. Therefore, catheter-based
intravascular imaging methods, such as optical coherence
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tomography (OCT) and NIRS are highly valuable for detailed
characterization of coronary atherosclerotic plaques, and have
become available within the last years.
As described above, the NIRS imaging system allowing for
plaque assessment was carefully validated against atherosclerot-
ic plaque autopsy specimens, and can nowadays be used in
humans in vivo [7, 8]. A summary of recent clinical investiga-
tions is outlined in Table 1. NIRS provides excellent spectra
through blood and despite heart movement by using short
scanning acquisition cycles [7]. The PROSPECT study sug-
gested, that a plaque burden of >70 %, thin-cap fibroatheroma,
and minimal luminal area ≤4.0 mm2 are predictors of overall
long-term adverse cardiovascular events [9]. NIRS has been
established as a very accurate modality to characterize plaques
with different lipid content [8]. Madder et al. have shown, that
target lesions responsible for acute coronary syndrome are fre-
quently composed of lipid core plaque with a high lipid core
burden index (LCBI) [10]. The presence of lipid core plaque
may address the high-risk setting for subsequent coronary
events, which needs to be further investigated in future studies
[11, 12]. Interestingly, both culprit and non-culprit lesions
contained lipid core plaque more frequently in ACS patients as
compared to patients with stable angina [10].
Moreover, the study by Pu et al. have recently supported the
notion, that combining NIRS with IVUS can lead to a better
plaque characterization [13]. In addition, the three-dimensional
reconstruction of coronary anatomy by ANGIOCARE
Software permits the identification of the lipid core plaque
location and therefore the association among vessel geometry,
endothelial shear stress and plaque composition [14].
Implications for Guiding Therapy
The impact of short-term intensive statin treatment on a lipid
plaque content has been investigated in a first study using NIRS
demonstrating changes in lipid composition [15]. Several small
studies have examined the potential impact of plaque evaluation
by NIRS for interventional coronary therapy [16–18]. It is well
known, that 3-15 % of percutaneous coronary interventions
(PCIs) are complicated by periprocedural myocardial infarction
(MI) due to the distal embolization by intraluminal thrombus
and/or lipid-core plaque content [19–21]. First studies suggest
that edge dissections or plaque disruptionsmay bemore common
when stents end within a lipid core plaque [22]. Dixon et al. have
documented, that in 16% of lesions lipid core plaquemay extend
Fig. 1 An example of near-
infrared spectroscopy (NIRS). A
‘chemogram’ is shown detecting
a colour map of the artery wall
and indicates the location and
intensity of coronary lipid
content. The horizontal-axis of
the chemogram represents the
pullback position and the vertical-
axis represents the circumferential
position in degrees (0–360°).
Adapted and modified from: Choi
B et al. Eur Heart J
2013;34:2047–2054
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beyond the margins of the lesion as assessed by angi-
ography [23]. This further points to limitations of QCA
alone in the evaluation of lesion- and subsequently stent
length [23]. Notably, the NIRS-identified lipid core
plaque has been described to be strongly associated with a
high risk of thrombus formation or periprocedural myocardial
infarction [17, 18, 24].
Future Perspectives
NIRS is likely to become a sensitive modality for coronary
plaque characterization. NIRS could be an interesting tool to
investigate novel lipid-modulating and other cardiovascular
therapies aiming to prevent adverse coronary events [17, 23].
However, a potential limitation of NIRSmay be its inability to
assess the depth of a lipid core and the measurement of lipid
volume has not been validated so far [5]. NIRS may therefore
be used in combination with other imaging modalities, such as
IVUS or OCT. In this respect, a combined imaging catheter has
recently been developed (TVC Imaging System, MC 7 system,
InfraReDx, Burlington,Massachusetts, USA), combining both,
an IVUS probe and NIRS light source. This catheter is being
used in the IBIS-3 (Integrated Biomarker and Imaging Study 3)
to investigate the effects of rosuvastatin therapy on the lipid-
rich coronary atherosclerotic plaques [25].
Fig. 2 Near-infrared spectroscopy
(NIRS) imaging indicates the
lipid-core containing plaques are
substantially more frequent in
human coronary arteries with
endothelial dysfunction. Adapted
and modified from: Choi B et al.
Eur Heart J 2013;34:2047–2054
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Table 1 Intracoronary human NIRS studies
Study Year n* patients Aim Conclusion
Caplan J.D. et .al [6] 2006 6 Initial clinical experience in stable CAD High quality NIRS spectra can be obtained in patients
in vivoJACC
Waxman, S. et .al [7] 2009 106 To determine whether catheter-based NIRS signals
from coronaries of patients are similar to those
from autopsy specimens and to assess initial
safety of NIRS device
Spectral data were safely obtained by NIRS similarly
to those from autopsy specimens; results
demonstrated the feasibility of invasive detection
of coronary LCP
JACC Cardiovasc Imaging
Raghunathan, D. et .al [17] 2011 30 To examine whether an association exists between
the presence and extent of LCP detected by NIRS
performed before PCI with postprocedural MI
PCI of LCP-positive lesions is associated with
increased risk for MI after PCIAm J Cardiol
Goldstein, J.A. et .al [18] 2011 62 To analyze the relationship between the presence
of a large LCP detected by NIRS and
periprocedural MI
NIRS provides rapid, automated detection of
extensive LCPs that are associated with a high risk
of periprocedural MI
Circ Cardiovasc Interv
Brugaletta, S. et .al [26] 2011 31 To compare the findings of NIRS, IVUS virtual
histology and grayscale IVUS obtained in
matched coronary vessel segments of patients
undergoing coronary angiography
Larger plaque area by grayscale IVUS was more
often associated with either elevated percentage
VH necrotic core or LCP by NIRS
JACC Cardiovasc Imaging
Madder, R.D. et .al [10] 2012 60 To determine the frequency of LCP at target and
remote sites in ACS vs. stable angina
Target lesion responsible for ACS were frequently
composed of LCP; LCPs oftenwere found in remote,
non-target areas; LCPs were more common in
patients with ACS vs. stable angina patients
Circ Cardiovasc Interv
Pu, J. et .al [13] 2012 66 To evaluate NIRS combined with IVUS to provide
novel information of human coronary plaque
characterization
CombiningNIRS and IVUS contributes to the plaque
characterizationEur Heart J
Dixon, S.R. et .al [23] 2012 69 To compare the target lesion length using NIRS
combined with angiography vs. angiography
alone
Patients undergoing stent implantation could have
LCP extending beyond the intended treatment
margins as defined using QCA alone
Am J Cardiol
Brugaletta, S. et .al [27] 2012 202 To explore a relationship between lipid plaque
composition by NIRS and angiographic severity
of coronary artery disease
Patients with highest Syntax score have a higher
LCBIJACC Cardiovasc Imaging
Brilakis, E.S. et .al [16] 2012 9 To investigate whether use of an embolic protection
device might prevent complications of LCP
interventions
Use of embolic protection devices frequently resulted
in embolized material retrieval after stenting of
native coronary artery lesions with large LCP
Catheter Cardiovasc
Interv
Brugaletta, S. et .al [28] 2012 68 To assess LCP distribution in nonculprit coronary
arteries using NIRS
LCP were mainly located in proximal portions of the
LAD and LCX, and more uniformly distributed in
the RCA;
JACC Cardiovasc Imaging
Kini, A.S. et .al [15] 2013 87 To determine the impact of short-term intensive statine
treatment on intracoronary plaque lipid content
Short-term intensive treatment with statine may reduce
lipid content in obstructive coronary lesionsJACC
Papayannis, A.C. et .al [24] 2013 9 To examine the association between presenting
LCP (by NIRS) and poststenting thrombus
formation (by OCT)
Stenting large LCPs may be associated with
intrastent thrombus formationCatheter Cardiovasc
Interv
Townsend, J.C. et .al [29] 2013 100 To investigate, whether coronary bifurcations have
higher levels of intracoronary LCP than non-
bifurcation regions
Coronary bifurcations do not appear to have higher
levels of intracoronary LCP than their comparative
non-bifurcation regions
Am J Cardiol
Maini, A. et .al [30] 2013 77 To evaluate LCP modification with coronary
revascularization and its correlation with
periprocedural MI
Plaque modification may be performed successfully
using interventional methods and can be evaluated
with NIRS; axial plaque shifting is an acute
prognostic marker for postprocedure MI
J Inv Cardiol
Madder, R.D. et .al [31] 2013 20 To describe NIRS findings of culprit lesions in
STEMI
Plaques causing STEMI have a high LCBI
JACC Cardiovasc Interv
Zynda, T.K. et .al [32] 2013 78 To determine if there was a relationship between
angiographic lesion complexity and the extent
of LCP identified by catheter-based NIRS
Angiographic SYNTAX score weakly correlated
with lipid core burden indexCatheter Cardiovasc
Interv
Choi, B.J. et .al [33] 2013 32 To investigate whether coronary endothelial
dysfunction is associated with the LCP in
patients with early CAD
Patients with early CAD and endothelial dysfunction
had a higher lipid content in the vascular wall than
patients with normal endothelial function;
Eur Heart J
ACS acute coronary syndrome;CAD coronary artery disease; IVUS intravascular ultrasound; LAD left artery descending; LCBI lipid core burden index;LCP
lipid core-containing plaque; LCX left circumflex artery;MI myocardial infarction;NIRS near-infrared spectroscopy; PCI percutaneous coronary intervention;
QCA Quantitative Coronary Angiography; RCA right coronary artery; STEMI ST-segment elevation myocardial infarction; *number of patients
Curr Cardiovasc Imaging Rep (2013) 6:426–430 429
Compliance with ethics Guidelines
Conflicts of Interest Dr. Milosz Jaguszewski and Dr. Roland
Klingenberg reported no conflicts of interest relevant to this article.
Dr. Ulf Landmesser serves as a SectionEditor forCurrent Cardiovascular
Imaging Reports.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Libby P. Mechanisms of acute coronary syndromes and their impli-
cations for therapy. N Engl J Med. 2013;368:2004–13.
2. Cassis LA, Lodder RA. Near-ir imaging of atheromas in living
arterial tissue. Anal Chem. 1993;65:1247–56.
3. Wang J, Geng YJ, Guo B, Klima T, Lal BN, et al. Near-infrared
spectroscopic characterization of human advanced atherosclerotic
plaques. J Am Coll Cardiol. 2002;39:1305–13.
4. Moreno PR,Muller JE. Identification of high-risk atherosclerotic plaques:
a survey of spectroscopic methods. Curr Opin Cardiol. 2002;17:638–47.
5. Jang IK. Near infrared spectroscopy: another toy or indispensible
diagnostic tool? Circ Cardiovasc Interv. 2012;5:10–1.
6. Caplan JD, Waxman S, Nesto RW, Muller JE. Near-infrared spec-
troscopy for the detection of vulnerable coronary artery plaques. J
Am Coll Cardiol. 2006;47:C92–6.
7. Waxman S, Dixon SR, L’Allier P, Moses JW, Petersen JL, et al. In
vivo validation of a catheter-based near-infrared spectroscopy system
for detection of lipid core coronary plaques: Initial results of the
spectacl study. JACC Cardiovasc Imaging. 2009;2:858–68.
8. Gardner CM, Tan H, Hull EL, Lisauskas JB, Sum ST, et al. Detection
of lipid core coronary plaques in autopsy specimens with a novel
catheter-based near-infrared spectroscopy system. JACC Cardiovasc
Imaging. 2008;1:638–48.
9. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, et al. A
prospective natural-history study of coronary atherosclerosis. N Engl
J Med. 2011;364:226–35.
10. Madder RD, Smith JL, Dixon SR, Goldstein JA. Composition of target
lesions by near-infrared spectroscopy in patients with acute coronary
syndrome versus stable angina. Circ Cardiovasc Interv. 2012;5:55–61.
11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, et al. From
vulnerable plaque to vulnerable patient: a call for new definitions and
risk assessment strategies: part I. Circulation. 2003;108:1664–72.
12. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, et al. From
vulnerable plaque to vulnerable patient: a call for new definitions and
risk assessment strategies: part II. Circulation. 2003;108:1772–8.
13. Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR, et al. In
vivo characterization of coronary plaques: novel findings from com-
paring greyscale and virtual histology intravascular ultrasound and
near-infrared spectroscopy. Eur Heart J. 2012;33:372–83.
14. Wentzel JJ, van der Giessen AG, Garg S, Schultz C, Mastik F, et al. In
vivo 3d distribution of lipid-core plaque in human coronary artery as
assessed by fusion of near infrared spectroscopy-intravascular ultrasound
and multislice computed tomography scan. Circ Cardiovasc Imaging.
2010;3:e6–7.
15. Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, et al. Changes in
plaque lipid content after short-term intensive versus standard statin
therapy: the yellow trial (reduction in yellow plaque by aggressive
lipid-lowering therapy). J Am Coll Cardiol. 2013;62:21–9.
16. Brilakis ES, Abdel-Karim AR, Papayannis AC, Michael TT, Rangan
BV, et al. Embolic protection device utilization during stenting of native
coronary artery lesions with large lipid core plaques as detected by near-
infrared spectroscopy. Catheter Cardiovasc Interv. 2012;80:1157–62.
17. Raghunathan D, Abdel-Karim AR, Papayannis AC, daSilva M, Jeroudi
OM, et al. Relation between the presence and extent of coronary lipid
core plaques detected by near-infrared spectroscopy with
postpercutaneous coronary intervention myocardial infarction. Am J
Cardiol. 2011;107:1613–8.
18. Goldstein JA, Maini B, Dixon SR, Brilakis ES, Grines CL, et al.
Detection of lipid-core plaques by intracoronary near-infrared spec-
troscopy identifies high risk of periprocedural myocardial infarction.
Circ Cardiovasc Interv. 2011;4:429–37.
19. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in
humans. J Am Coll Cardiol. 2009;54:281–92.
20. Prasad A, Herrmann J. Myocardial infarction due to percutaneous
coronary intervention. N Engl J Med. 2011;364:453–64.
21. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, et al.
Coronary microembolization: from bedside to bench and back to
bedside. Circulation. 2009;120:1822–36.
22. Saeed B, Banerjee S, Brilakis ES. Slow flow after stenting of a
coronary lesion with a large lipid core plaque detected by near-
infrared spectroscopy. EuroIntervention. 2010;6:545.
23. Dixon SR, Grines CL, Munir A, Madder RD, Safian RD, et al.
Analysis of target lesion length before coronary artery stenting using
angiography and near-infrared spectroscopy versus angiography
alone. Am J Cardiol. 2012;109:60–6.
24. Papayannis AC, Abdel-Karim AR, Mahmood A, Rangan BV, Makke
LB, et al. Association of coronary lipid core plaque with intrastent
thrombus formation: a near-infrared spectroscopy and optical coher-
ence tomography study. Catheter Cardiovasc Interv. 2013;81:488–93.
25. Simsek C, Garcia-Garcia HM, van Geuns RJ, Magro M, Girasis C,
et al. The ability of high dose rosuvastatin to improve plaque compo-
sition in non-intervened coronary arteries: rationale and design of the
integrated biomarker and imaging study-3 (ibis-3). EuroIntervention.
2012;8:235–41.
26. Brugaletta S, Garcia-GarciaHM, Serruys PW, deBoer S, Ligthart J, et al.
Nirs and ivus for characterization of atherosclerosis in patients undergo-
ing coronary angiography. JACC Cardiovasc Imaging. 2011;4:647–55.
27. Brugaletta S, Magro M, Simsek C, Heo JH, de Boer S, et al. Plaque
compositional syntax score: combining angiography and lipid burden in
coronary artery disease. JACC Cardiovasc Imaging. 2012;5:S119–21.
28. Brugaletta S, Garcia-Garcia HM, Serruys PW, Gomez-Lara J, de Boer S,
et al. Distance of lipid core-rich plaques from the ostium by nirs in
nonculprit coronary arteries. JACC Cardiovasc Imaging. 2012;5:297–9.
29. Townsend JC, Steinberg DH, Nielsen CD, Todoran TM, Patel CP,
et al. Comparison of lipid deposition at coronary bifurcations versus
at nonbifurcation portions of coronary arteries as determined by near-
infrared spectroscopy. Am J Cardiol. 2013;112:369–72.
30. Maini A, Buyantseva L, Maini B. In vivo lipid core plaque modifi-
cation with percutaneous coronary revascularization: a near-infrared
spectroscopy study. J Invasive Cardiol. 2013;25:293–5.
31. Madder RD,Goldstein JA,Madden SP, Puri R,Wolski K, et al. Detection
by near-infrared spectroscopy of large lipid core plaques at culprit sites in
patients with acute st-segment elevation myocardial infarction. JACC
Cardiovasc Interv. 2013. doi:10.1016/j.jcin.2013.04.012.
32. Zynda TK, Thompson CD, Hoang KC, Seto AH, Glovaci D, et al.
Disparity between angiographic coronary lesion complexity and lipid
core plaques assessed by near-infrared spectroscopy. Catheter Cardiovasc
Interv. 2013;81:529–37.
33. Choi BJ, Prasad A, Gulati R, Best PJ, Lennon RJ, et al. Coronary
endothelial dysfunction in patients with early coronary artery disease is
associated with the increase in intravascular lipid core plaque. Eur Heart
J. 2013;34:2047–54.
430 Curr Cardiovasc Imaging Rep (2013) 6:426–430
